CervoMed Inc.
$ 2.45
0.41%
12 Jun - close price
- Market Cap 22,683,900 USD
- Current Price $ 2.45
- High / Low $ 2.61 / 2.37
- Stock P/E N/A
- Book Value 1.15
- EPS -3.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.72 %
- ROE -1.33 %
- 52 Week High 11.25
- 52 Week Low 2.13
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$19.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-18 | 2026-03-13 | 2025-11-07 | 2025-08-08 | 2025-05-12 | 2025-03-17 | 2024-11-12 | 2024-08-09 | 2024-05-14 | 2024-03-25 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.86 | -0.88 | -0.84 | -0.7 | -0.56 | -0.8 | -0.5462 | -0.27 | -0.41 | -0.38 | -0.7 | -1.5537 |
| Estimated EPS | -0.7929 | -0.7017 | -0.46 | -0.68 | -0.6233 | -0.6343 | -0.41 | -0.31 | -0.39 | -0.29 | -0.95 | -2.9 |
| Surprise | -0.0671 | -0.1783 | -0.38 | -0.02 | 0.0633 | -0.1657 | -0.1362 | 0.04 | -0.02 | -0.09 | 0.25 | 1.3463 |
| Surprise Percentage | -8.4626% | -25.4097% | -82.6087% | -2.9412% | 10.1556% | -26.1233% | -33.2195% | 12.9032% | -5.1282% | -31.0345% | 26.3158% | 46.4241% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-06-13 03:09:32
CervoMed Inc. will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit virtually on Monday, June 15, 2026. Company management will engage in a fireside chat and one-on-one investor meetings to discuss their clinical-stage biotechnology efforts, including their lead drug neflamapimod for age-related brain disorders. A webcast of the fireside chat will be available on the CervoMed website.
2026-06-12 14:40:26
The article discusses the significant pre-market crash of CRVO stock by 22%. It delves into the potential reasons behind this sharp decline, providing insights for investors.
2026-06-12 14:39:11
CervoMed Inc. announced that its management will participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The company, which focuses on treatments for age-related brain disorders, will hold a fireside chat and one-on-one investor meetings virtually on Monday, June 15, 2026. CervoMed's lead drug candidate, neflamapimod, is currently in clinical trials for conditions like DLB, nfvPPA, and ALS.
2026-06-11 14:39:11
CervoMed Inc. director Frank Zavrl was granted 8,150 stock options on June 8, 2026, as part of his non-employee director compensation. The options have an exercise price of $2.91 per share under the 2025 Equity Incentive Plan and will vest monthly over one year, starting June 30, 2026. Following this grant, Zavrl directly holds 8,150 stock options.
2026-06-11 03:09:32
CervoMed Inc. has announced a private placement financing expected to gross $10.5 million, extending its cash runway into Q2 2027. The company plans to use these funds and pursue strategic partnerships to advance its lead drug candidate, neflamapimod, into Phase 3 clinical trials for dementia with Lewy bodies (DLB). CervoMed also outlined upcoming milestones for neflamapimod in additional rare neurological disorders, including nonfluent variant primary progressive aphasia (nfvPPA) and amyotrophic lateral sclerosis (ALS).
2026-06-11 02:39:42
CervoMed Inc. director Jane H. Hollingsworth was granted stock options for 8,150 shares with an exercise price of $2.91 per share, following her election to the board. The options, granted under the company's 2025 Equity Incentive Plan, expire on June 8, 2036. The shares will vest monthly over one year starting June 30, 2026, contingent on her continued board service.
